Literature DB >> 23331831

Toxic shock syndrome due to group A beta-hemolytic streptococcus presenting with purpura fulminans and limb ischemia in a pediatric patient treated with early microsurgical arteriolysis.

Maria-Anna Daskalaki1, Willy D Boeckx, Albert DeMey, Diane Franck.   

Abstract

We describe a 2.5 year-old child with toxic shock syndrome due to group A beta-hemolytic streptococcus (GABHS) who presented with purpura fulminans and limb ischemia treated with early microsurgical arteriolysis. The clinical picture of toxic shock syndrome (TSS) presenting with purpura fulminans and limb ischemia is an exceptionally uncommon finding in sepsis due to GABHS. This is the first case of purpura fulminans caused by GABHS reported in Europe and the third one described in the literature (Dhodapkar et al., 2000[1]; Renaud et a., 2011[2]).
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23331831     DOI: 10.1016/j.jpedsurg.2012.09.057

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  3 in total

1.  Identification of differentially expressed serum proteins in infectious purpura fulminans.

Authors:  Ting He; Jiong-yu Hu; Jian Han; Dong-xia Zhang; Xu-pin Jiang; Bing Chen; Yue-sheng Huang
Journal:  Dis Markers       Date:  2014-02-10       Impact factor: 3.434

2.  Acute infectious purpura fulminans caused by group A β-hemolytic Streptococcus: An uncommon organism.

Authors:  Divya Gupta; Laxmisha Chandrashekar; Bheemanathi Hanuman Srinivas; Devinder Mohan Thappa
Journal:  Indian Dermatol Online J       Date:  2016 Mar-Apr

Review 3.  Streptococcus pyogenes-purpura fulminans as an invasive form of group A streptococcal infection.

Authors:  Sayaka Okuzono; Masataka Ishimura; Shunsuke Kanno; Motoshi Sonoda; Noriyuki Kaku; Yoshitomo Motomura; Hisanori Nishio; Utako Oba; Masuo Hanada; Jun-Ichi Fukushi; Michiyo Urata; Dongchon Kang; Hidetoshi Takada; Shouichi Ohga
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-07-09       Impact factor: 3.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.